In 1999, Nabel was appointed as the founding director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases under the NIH. The VRC focused on laboratory research and clinical trials of vaccines, including over 100 studies for vaccine candidates against SARS, Chikungunya, Influenza, and Ebola.[9] Notable developments during Nabel's tenure at the VRC include research into the immune mechanisms of protection against Ebola that would inform the development of the vesicular stomatitis virus-based Ebola vaccine (VSV-EBOV),[10] and the discovery of broadly neutralizing antibodies to the highly conserved CD4 binding site of HIV, later tested in human efficacy trials.[11]
In 2012, Nabel joined Sanofi as Chief Scientific Officer. In addition to continuing his work on neutralizing antibodies against HIV, he led research on antibody-mediated stimulation of CD8 T cells in cancer using novel multi-specific antibodies.[12][13][14] In 2020, Nabel co-founded ModeX Therapeutics, a clinical-stage biopharmaceutical company primarily focusing on these multi-specific antibodies. ModeX was acquired by OPKO Health in 2022.[15][16]
Nabel has held positions on various scientific advisory boards and councils, including Chairman of the Strategic Development and Scientific Advisory Council (SDSAC).[17]
Nabel served as the Chair of the Board of Directors for the Keystone Symposia[20] from 2017 to 2019. He was a Council Delegate to the AAAS, Medical Sciences Section, from 1997 to 2002, and was the editor for the Journal of Virology from 1995 to 2005.
↑Nabel, Gary; Baltimore, David (1987). "An inducible transcription factor activates expression of human immunodeficiency virus in T cells". Nature. 326 (6114): 711–713. Bibcode:1987Natur.326..711N. doi:10.1038/326711a0. PMID3031512.
↑Nabel, G. J.; Nabel, E. G.; Yang, Z. Y.; Fox, B. A.; Plautz, G. E.; Gao, X.; Huang, L.; Shu, S.; Gordon, D.; Chang, A. E. (1993-12-01). "Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans". Proceedings of the National Academy of Sciences. 90 (23): 11307–
↑7. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. "Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6(243):243ra88, 2014.
12Infections, Institute of Medicine (US) Forum on Emerging; Knobler, Stacey L.; Mahmoud, Adel AF; Pray, Leslie A. (2002), "Forum Member, Speaker, and Staff Biographies", Biological Threats and Terrorism: Assessing The Science and Response Capabilities: Workshop Summary, National Academies Press (US), retrieved 2024-11-24
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
